Association Between NSAIDs use and Female Breast Cancer Risk
MetadataShow full item record
Evaluation of aspirin and non-aspirin non-steroidal anti-inflammatory drugs (NA NSAIDs) as potential chemopreventive agents for breast cancer have been investigated in many epidemiological studies with inconsistent results. These drugs have been the focus of considerable breast cancer research for the past two decades. Several risk factors for breast cancer have been well documented. However, for most women presenting with breast cancer definite risk factors are not identifiable. Existing data has implicated inflammation as a risk factor for different types of cancer, including breast cancer. To evaluate the effect of aspirin and NA NSAIDs on the risk of female breast cancer we carried out a hospital-based case- control study using autonomous individuals from the Data Bank and bio-repository (DBBR) at Roswell Park Cancer Institute RPCI 2009-2011. There were 1,043 participants with histologically confirmed breast cancer and no other primary cancer or history of cancer. Thirty-seven percent of controls (n = 1,043) included patients' family, friends, or visitors and were matched on age and race. The rest of the controls included volunteers and members of the community. Unconditional logistic regression was used to estimate crude and adjusted odds ratios (ORs), with corresponding 95% confidence intervals (CI). The adjusted odds ratio for regular (≥ 1 day for full year) aspirin use was 1.02 (95% CI: 0.82-1.25). Regular ibuprofen and acetaminophen use showed null results. The effect of aspirin use on breast cancer risk did not vary according to menopausal status. Adult lifetime aspirin use of more than 20 years of use was associated with a decreased risk of breast cancer (any use > 30 yrs., OR = 0.82, 95% CI: 0. 57-1.18). Although our efforts showed null results, the methodological limitations of hospital case-control studies should be considered.